ClinicalTrials.gov record
Completed Early Phase 1 Interventional

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT05891119

Public ClinicalTrials.gov record NCT05891119. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 5:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-label, Drug-Drug Interaction Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple CYP450 Substrates in Patients With Moderate to Severe Atopic Dermatitis

Study identification

NCT ID
NCT05891119
Recruitment status
Completed
Study type
Interventional
Phase
Early Phase 1
Lead sponsor
Amgen
Industry
Enrollment
21 participants

Conditions and interventions

Interventions

  • Caffeine Dietary Supplement
  • Metoprolol Drug
  • Midazolam Drug
  • Omeprazole Drug
  • Rocatinlimab Drug
  • Vitamin K Dietary Supplement
  • Warfarin Drug

Dietary Supplement · Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2, 2023
Primary completion
Aug 27, 2024
Completion
Feb 11, 2025
Last update posted
Dec 22, 2025

2023 – 2025

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Velocity Clinical Research, North Hollywood North Hollywood California 91606-1570
Accel Research Sites (ACR) DeLand Florida 32720-3134
Direct Helpers Research Center (DHRC) Hialeah Florida 33012-3618
Axis Clinicals, LCC Dilworth Minnesota 56529
DermDox Dermatology Centers, PC - Camp Hill Camp Hill Pennsylvania 17011
Velocity Clinical Research -Spartanburg Spartanburg South Carolina 29303-4225
DermDox Dermatology Centers, PC - Sugarloaf Nashville Tennessee 37203-1632

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05891119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 22, 2025 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05891119 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →